Gao Y, Kong F, Song X, Shang J, Yao L, Xia J, Peng Y, Liu W, Gong H, Mu M, Cui H, Han T, Chen W, Wu X, Yang Y, Yan X, Jin Z, Wang P, Zhu Q, Chen L, Zhao C, Zhang D, Jin W, Wang D, Wen X, Liu C, Jia J, Mao Q, Ding Y, Jin X, Zhang Z, Mao Q, Li G, Niu J
and liver protection with anti-fibrotic and cytoprotective properties
Their main side effects are usually nausea and vomiting. In TRIUMPH-2, up to 11.6 percent of participants using retatrutide stopped the drug before the end of the trial due to side effects, compared with 4.9 percent of the placebo group
Our comprehensive redox profiling across various cancer types and age-related neurodegenerative diseases revealed modified redox fingerprints, major changes in the correlative patterns of the metabolites with each other, differing from the healthy controls
Klausen MK, Jensen ME, Mller M, Le Dous N, Jensen A-M, Zeeman VA, Johannsen C-F, Lee A, Thomsen GK, Macoveanu J, Fisher PM, Gillum MP, Jrgensen NR, Bergmann ML, Poulsen HE, Becker U, Holst JJ, Benveniste H, Volkow ND, Fink-Jensen A (2022a) Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial
Physiological Relevance: Its still debated whether GLP-3 has significant independent biological activity or if its primarily a byproduct of proglucagon processing
